Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma
Brief Summary: RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of bevacizumab given together with lomustine is most effective in treating patients with glioblastoma multiforme in first recurrence.

PURPOSE: The primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone.


Options:
A: Arm Label: Arm A: SRT to the resection cavity; Type: EXPERIMENTAL; Interventions: Radiation: SRT to the resection cavity | Arm Label: Arm B: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: RADIATION; Name: SRT to the resection cavity; Assigned to Arm(s): Arm A: SRT to the resection cavity
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: cognitive assessment; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm 1, Arm 2
C: Arm Label: Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Arm Label: Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: KLH | Arm Label: Group 2 and 2C: Refractory to Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control, Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control
D: Arm Label: ARM A - Regorafenib; Type: EXPERIMENTAL; Interventions: Drug: Regorafenib | Arm Label: ARM B - Lomustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine | Intervention Type: DRUG; Name: Regorafenib; Assigned to Arm(s): ARM A - Regorafenib | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): ARM B - Lomustine

Answer: B